Transcriptome study of differential expression in schizophrenia.

Area of Science:

• Neuroscience
• Genetics
• Immunology

Background:

• Genome-wide association studies (GWAS) have identified genetic risk factors for schizophrenia but lack clarity on biological mechanisms.
• Regulatory variants are increasingly implicated in schizophrenia risk, suggesting a role for altered gene expression.

Purpose of the Study:

• To identify gene expression abnormalities in schizophrenia by analyzing whole-genome expression profiles.
• To uncover novel candidate genes contributing to schizophrenia pathophysiology.

Main Methods:

• Whole-genome gene expression profiling using microarrays on lymphoblastoid cell lines (LCLs) from 413 schizophrenia cases and 446 controls.
• Regression analysis controlling for confounding effects to identify differentially expressed transcripts at a genome-wide false discovery rate (FDR) of 0.05.

Main Results:

• Identified 95 transcripts (89 genes) differentially expressed in schizophrenia cases versus controls.
• Enrichment of immune-related genes, including histones in the extended Major Histocompatibility Complex (xMHC) region, aligning with GWAS findings.
• Differential expression of B3GNT2 and DICER1 suggests links to autoimmune disorders and microRNA (miRNA) processing alterations relevant to schizophrenia.

Conclusions:

• Schizophrenia exhibits functional diversity in gene expression, involving neurotransmission, immune responses, and gene regulation.
• Immune system dysregulation is a potential contributor to schizophrenia risk.
• Novel candidate genes, particularly within the xMHC region and involved in miRNA processing, warrant further investigation for their role in schizophrenia.